Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.53 |
| ▸ | NOS3 | P29474 | 10/20 | 0.53 |
| ▸ | NOS1 | P29475 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16389765 | 0.84 | ALDH1A1 (0.36) | NOS2NOS3NOS1 | |
| SCHEMBL16964842 | 0.78 | NOS2 (0.53) | NOS2NOS3NOS1 | |
| SCHEMBL9426089 | 0.77 | KDM4E (0.36) | NOS2NOS3NOS1 | |
| SCHEMBL2614502 | 0.77 | NOS3 (0.44) | NOS2NOS3NOS1 | |
| SCHEMBL25778174 | 0.76 | L3MBTL1 (0.40) | NOS3NOS1 | |
| SCHEMBL105871 | 0.75 | — | — | |
| SCHEMBL29745979 | 0.74 | MBOAT4 (0.40) | NOS2NOS1 | |
| SCHEMBL21355701 | 0.74 | MBOAT4 (0.40) | NOS2NOS1 | |
| SCHEMBL8687439 | 0.74 | MEN1 (0.32) | NOS2NOS3NOS1 | |
| SCHEMBL1162976 | 0.74 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2017027345-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS2 4218/4885NOS3 4412/4885NOS1 4483/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS2 4218/4885NOS3 4412/4885NOS1 4483/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS2 4218/4885NOS3 4412/4885NOS1 4483/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS2 4218/4885NOS3 4412/4885NOS1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.